Astrazeneca annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca R&D Spending Growth & History (AZN)
Astrazeneca's r&d spending was $14.23B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.23B | $649.0M | +4.78% |
| 2024 | 2024-12-31 | $13.58B | $2.65B | +24.22% |
| 2023 | 2023-12-31 | $10.94B | $1.17B | +12.02% |
| 2022 | 2022-12-31 | $9.76B | $26.0M | +0.27% |
| 2021 | 2021-12-31 | $9.74B | $3.75B | +62.51% |
| 2020 | 2020-12-31 | $5.99B | −$68.0M | −1.12% |
| 2019 | 2019-12-31 | $6.06B | $127.0M | +2.14% |
| 2018 | 2018-12-31 | $5.93B | $175.0M | +3.04% |
| 2017 | 2017-12-31 | $5.76B | −$133.0M | −2.26% |
| 2016 | 2016-12-31 | $5.89B | −$107.0M | −1.78% |
| 2015 | 2015-12-31 | $6.00B | — | — |
Astrazeneca quarterly r&d spending
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.05B | $505.0M | +14.23% |
| Q1 2026 | 2026-03-31 | $3.49B | — | — |
| Q4 2025 | 2025-12-31 | $3.86B | — | — |
| Q3 2025 | 2025-09-30 | $3.66B | — | — |
| Q2 2025 | 2025-06-30 | $3.55B | $540.0M | +17.95% |
| Q2 2024 | 2024-06-30 | $3.01B | $341.0M | +12.79% |
| Q2 2023 | 2023-06-30 | $2.67B | $121.0M | +4.75% |
| Q2 2022 | 2022-06-30 | $2.55B | $717.0M | +39.20% |
| Q2 2021 | 2021-06-30 | $1.83B | $440.0M | +31.68% |
| Q2 2020 | 2020-06-30 | $1.39B | $33.0M | +2.43% |
| Q2 2019 | 2019-06-30 | $1.36B | −$6.0M | −0.44% |
| Q2 2018 | 2018-06-30 | $1.36B | $13.0M | +0.96% |
| Q2 2017 | 2017-06-30 | $1.35B | — | — |
Astrazeneca r&d spending trends
Over the last five fiscal years, Astrazeneca's r&d spending increased from $5.99B to $14.23B, a change of $8.24B. The latest reported quarter, Q2 2026, shows $4.05B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...